keyword
MENU ▼
Read by QxMD icon Read
search

Cd22

keyword
https://www.readbyqxmd.com/read/30513380/transcriptomic-analysis-of-immunity-in-rainbow-trout-oncorhynchus-mykiss-gills-infected-by-ichthyophthirius-multifiliis
#1
Khairul Syahputra, Per W Kania, Azmi Al-Jubury, Rzgar M Jafaar, Ron P Dirks, Kurt Buchmann
The parasite Ichthyophthirius multifiliis infecting skin, fins and gills of a wide range of freshwater fish species, including rainbow trout, is known to induce a protective immune response in the host. Although a number of studies have reported activation of several immune genes in infected fish host, the immune response picture is still considered incomplete. In order to address this issue, a comparative transcriptomic analysis was performed on infected versus uninfected rainbow trout gills and it showed that a total of 3352 (7...
December 1, 2018: Fish & Shellfish Immunology
https://www.readbyqxmd.com/read/30504288/no-free-rides-management-of-toxicities-of-novel-immunotherapies-in-all-including-financial
#2
REVIEW
Tania Jain, Mark R Litzow
Therapeutic options for acute lymphoblastic leukemia, especially in the relapsed/refractory setting, have expanded significantly in recent times. However, this comes at the cost of toxicities: medical as well as financial. We highlight some of the unique toxicities associated with the novel agents to apprise our readers about what to expect, how to recognize them, and how to manage these toxicities. One of the toxicities seen with inotuzumab, a CD22 antibody drug conjugate, is sinusoidal obstruction syndrome, which can be fatal in >80% of patients if associated with multiorgan failure...
November 30, 2018: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/30504286/antibody-based-therapies-in-patients-with-acute-lymphoblastic-leukemia
#3
REVIEW
Shira Dinner, Michaela Liedtke
The use of multiagent combination chemotherapy regimens results in cure rates of >90% for children and ∼40% for adults with acute lymphoblastic leukemia (ALL) but is associated with extensive toxicity and disappointingly low efficacy in relapsed patients. ALL blast cells express several surface antigens, including CD20, CD22, and CD19, which represent valuable targets for immunotherapy. Monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell-engaging antibodies targeting these antigens offer novel mechanisms of action...
November 30, 2018: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/30482769/no-free-rides-management-of-toxicities-of-novel-immunotherapies-in-all-including-financial
#4
REVIEW
Tania Jain, Mark R Litzow
Therapeutic options for acute lymphoblastic leukemia, especially in the relapsed/refractory setting, have expanded significantly in recent times. However, this comes at the cost of toxicities: medical as well as financial. We highlight some of the unique toxicities associated with the novel agents to apprise our readers about what to expect, how to recognize them, and how to manage these toxicities. One of the toxicities seen with inotuzumab, a CD22 antibody drug conjugate, is sinusoidal obstruction syndrome, which can be fatal in >80% of patients if associated with multiorgan failure...
November 27, 2018: Blood Advances
https://www.readbyqxmd.com/read/30466749/should-immunologic-strategies-be-incorporated-into-frontline-all-therapy
#5
REVIEW
Cecilie Utke Rank, Wendy Stock
Survival rates in adult patients with acute lymphoblastic leukemia (ALL) have markedly improved during the past decade. The one-size-fits-all-ages approach has been replaced with adaptation of pediatric-inspired treatment protocols for younger adults. Yet different treatment strategies for older patients are needed due to chemotherapy-related toxicities. A new era of immunotherapy has arrived, offering opportunities for targeted treatments for ALL subtypes. While CD20 targeting with rituximab has been demonstrated to improve survival when combined with chemotherapy, it has little activity as a single agent in ALL...
December 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/30442119/inotuzumab-ozogamicin-is-effective-in-relapsed-refractory-extramedullary-b-acute-lymphoblastic-leukemia
#6
Luca Bertamini, Jacopo Nanni, Giovanni Marconi, Mariachiara Abbenante, Valentina Robustelli, Francesco Bacci, Antonella Matti, Stefania Paolini, Chiara Sartor, Silvia Lo Monaco, Maria Chiara Fontana, Stefano De Polo, Michele Cavo, Antonio Curti, Giovanni Martinelli, Cristina Papayannidis
BACKGROUND: Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin. CASE PRESENTATION: We report two cases of CD22 positive relapsed EM-ALL treated with IO, obtained as compassionate use...
November 15, 2018: BMC Cancer
https://www.readbyqxmd.com/read/30424518/transcriptome-analysis-provides-insights-into-the-markers-of-resting-and-lps-activated-macrophages-in-grass-carp-ctenopharyngodon-idella
#7
Yazhen Hu, Xiaolei Wei, Zhiwei Liao, Yu Gao, Xiaoling Liu, Jianguo Su, Gailing Yuan
Macrophages are very versatile immune cells, with the characteristics of a proinflammatory phenotype in response to pathogen-associated molecular patterns. However, the specific activation marker genes of macrophages have not been systematically investigated in teleosts. In this work, leukocytes (WBC) were isolated using the Percoll gradient method. Macrophages were enriched by the adherent culture of WBC, then stimulated with lipopolysaccharide (LPS). Macrophages were identified by morphological features, functional activity and authorized cytokine expression...
November 12, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/30372691/long-term-molecular-remission-achieved-by-antibody-anti-cd22-and-ponatinib-in-a-patient-affected-by-ph-acute-lymphoblastic-leukemia-relapsed-after-second-allogeneic-hematopoietic-stem-cell-transplantation-a-case-report
#8
Maria Cristina Pirosa, Salvatore Leotta, Alessandra Cupri, Stefania Stella, Enrica Antonia Martino, Luca Scalise, Giuseppe Sapienza, Valeria Calafiore, Elisa Mauro, Andrea Spadaro, Paolo Vigneri, Francesco Di Raimondo, Giuseppe Milone
Ph'+ acute lymphoblastic leukemia (Ph'+-ALL) is an oncohematologic disorder for which allogeneic bone marrow transplantation still offers the only chance of cure. However, relapse is the main reason for treatment failure, also after hematopoietic stem cell transplantation (HSCT). New drugs, such as third generation tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have expanded the therapeutic landscape, especially in patients who relapsed before HSCT. Very few reports, up to now, have described the use of both classes of these new agents in combination with donor lymphocyte infusions (DLI) in the setting of patients who relapsed after HSCT...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30362019/combining-biology-and-chemistry-for-a-new-take-on-chemotherapy-antibody-drug-conjugates-in-hematologic-malignancies
#9
REVIEW
Helen Ma, Ahmed Sawas
PURPOSE OF REVIEW: This review is about the antibody-drug conjugate (ADC), a form of drug delivery consisting of a monoclonal antibody, linker, and cytotoxic payload. We summarize the history of ADC development, highlighting the three FDA-approved ADCs currently available. RECENT FINDINGS: Gemtuzumab ozogamicin is a CD33-targeted ADC linked to calicheamicin. It is approved for CD33+ AML in the first line or the relapsed or refractory (R/R) setting. Brentuximab vedotin is a CD30-targeted ADC bound to MMAE...
October 25, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/30357593/moxetumomab-pasudotox-first-global-approval
#10
Sohita Dhillon
Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an optimised version of immunotoxin CAT-3888. Moxetumomab pasudotox is composed of the Fv fragment of an anti-CD22 monoclonal antibody fused to a 38 kDa fragment of Pseudomonas exotoxin A, PE38. The Fv portion of moxetumomab pasudotox binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumour cells...
November 2018: Drugs
https://www.readbyqxmd.com/read/30355653/downregulation-of-siglec-2-cd22-predicts-worse-overall-survival-from-hbv-related-early-stage-hepatocellular-carcinoma-a-preliminary-analysis-from-gene-expression-omnibus
#11
Xiaojing Ren, Yuanyuan Ji, Xuhua Jiang, Xun Qi
Sialic acid-binding immunoglobulin-like lectin (siglec) regulates cell death, anti-proliferative effects and mediates a variety of cellular activities. Little was known about the relationship between siglecs and HCC prognosis. Siglec gene expression between tumor and non-tumor tissues were compared and correlated with overall survival from HCC patients in GSE14520 microarray expression profile. Siglec-1 to siglec-9 were all down-regulated in tumor tissues compared to those in non-tumor tissues in HCC patients (all P < 0...
October 24, 2018: Bioscience Reports
https://www.readbyqxmd.com/read/30333834/ligand-recognition-determines-the-role-of-inhibitory-b-cell-co-receptors-in-the-regulation-of-b-cell-homeostasis-and-autoimmunity
#12
REVIEW
Takeshi Tsubata
B cells express various inhibitory co-receptors including CD22, CD72, and Siglec-G. These receptors contain immunoreceptor tyrosine-based inhibition motifs (ITIMs) in the cytoplasmic region. Although many of the inhibitory co-receptors negatively regulate BCR signaling by activating SH2-containing protein tyrosine phosphatase 1 (SHP-1), different inhibitory co-receptors have distinct functional properties. CD22, Siglec-G, and CD72 preferentially regulate tonic signaling in conventional B cells, B-1 cell homeostasis, and development of lupus-like disease, respectively...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/30323814/cd22-a-regulator-of-innate-and-adaptive-b-cell-responses-and-autoimmunity
#13
REVIEW
Edward A Clark, Natalia V Giltiay
CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized over 30 years ago and named "CD22" in 1984 at the 2nd International workshop in Boston (1). Several excellent reviews have detailed CD22 functions, CD22-regulated signaling pathways and B cell subsets regulated by CD22 or Siglec G (2-4). This review is an attempt to highlight recent and possibly forgotten findings. We also describe the role of CD22 in autoimmunity and the great potential for CD22-based immunotherapeutics for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE)...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/30305504/-strategy-for-treatment-of-acute-lymphoblastic-leukemia
#14
Yukio Kobayashi
The treatment outcomes of adult acute lymphoblastic leukemia (ALL) have improved. Furthermore, the introduction of pediatric specific therapies has enhanced ALL treatment results in adolescents and young adult (AYAs). Age-related molecular signatures have also been identified, such as Philadelphia chromosome (Ph)-like ALL and DUX4/ERG gene-associated ALL. The measurement of minimal residual disease (MRD) has enabled the early detection of patients susceptible to relapse, and they become candidates for hematopoietic stem cell transplantation (HSCT)...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/30295242/-relationship-between-immune-differentiation-antigen-and-minimal-residual-disease-in-childhood-b-all
#15
Yue-Fang Wang, Ge Zhang, Yong-Mei Jiang, Ju Gao
OBJECTIVE: To determine whether immune differentiation antigen is related with clinical features and minimal residual disease (MRD) in childhood B-cell precursor acute lymphoblastic leukemia (B-ALL), who were treated with CCCG-ALL-2015 protocol. METHODS: A retrospective analysis was conducted in 132 B-ALL children, Multiparametric flow cytometry was used to analyze the immunophenotypes. The children were divided into 2 groups by MRD>0.1% on d 19 and / or d 46 after chemotherapy...
October 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/30267011/inotuzumab-ozogamicin-in-pediatric-patients-with-relapsed-refractory-acute-lymphoblastic-leukemia
#16
Deepa Bhojwani, Richard Sposto, Nirali N Shah, Vilmarie Rodriguez, Constance Yuan, Maryalice Stetler-Stevenson, Maureen M O'Brien, Jennifer L McNeer, Elizabeth A Raetz, Mignon L Loh, Susan R Rheingold
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use program. In this heavily pretreated cohort, complete remission was achieved in 67% of patients with overt marrow disease. The majority (71%) of responders were negative for minimal residual disease. Responses were observed irrespective of cytogenetic subtype or number or type of prior treatment regimens...
September 28, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30266605/macropinocytosis-dependent-endocytosis-of-japanese-flounder-igm-b-cells-and-its-regulation-by-cd22
#17
Yi-Qun Li, Li Sun, Jun Li
B cells in fish are proven to be endocytic and have a great contribution to innate immunity like phagocytosis. In this study, the endocytic capacity and the corresponding internalization pathways of IgM+ B cells in Japanese flounder (Paralichthys olivaceus) were investigated. The results showed that IgM+ B cells in peripheral blood leukocytes (PBL) and splenic leukocytes (SL) exhibited different abilities to ingest 0.5 μm and 1 μm latex beads through macropinocytosis-dependent endocytic pathway. Japanese flounder CD22 (PoCD22) co-stimulatory signals were identified to be essential for the innate immune responses in B cells...
September 25, 2018: Fish & Shellfish Immunology
https://www.readbyqxmd.com/read/30262591/hairy-cell-leukemia-treatment-approved
#18
(no author information available yet)
The FDA approved moxetumomab pasudotox-tdfk, a CD22-directed recombinant immunotoxin, for patients with relapsed/refractory hairy cell leukemia who have not responded to at least two prior treatments, including a purine nucleoside analogue.
November 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30212602/flow-cytometric-monitoring-for-residual-disease-in-b-lymphoblastic-leukemia-post-t-cell-engaging-targeted-therapies
#19
Sindhu Cherian, Maryalice Stetler-Stevenson
The use of targeted therapy is growing in the setting of hematopoietic neoplasms. Flow cytometry is a cornerstone of residual disease monitoring post therapy in this group of malignancies. Often, there is overlap between antigens targeted by immunotherapies and gating reagents utilized for population identification by flow cytometry. Such overlap can render a previously excellent gating reagent inadequate for disease detection. Recently, several anti-CD19 T cell-engaging immunotherapeutic agents and an anti-CD22 immunotoxin have been FDA approved for use in B lymphoblastic leukemia (B-LL), with an anti-CD22 T cell-engaging agent in development...
October 2018: Current Protocols in Cytometry
https://www.readbyqxmd.com/read/30143587/sialic-acid-ligand-binding-of-cd22-and-siglec-g-determines-distinct-b-cell-functions-but-is-dispensable-for-b-cell-tolerance-induction
#20
Lamia Özgör, Sarah J Meyer, Marina Korn, Klara Terörde, Lars Nitschke
Siglec-G and CD22 are inhibitory receptors on B cells and play an important role in the maintenance of tolerance. Although both molecules are expressed on all B cell populations at a similar level, Siglec-G was found to regulate exclusively B1a cells, whereas CD22 functions as an inhibitory receptor specifically on B2 cells. It is known that the mechanistic function of both Siglecs is regulated by sialic acid binding in a reciprocal manner, although it was not known until now how B cells would act when both Siglec-G and CD22 lack their ability to bind sialic acids...
October 1, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
keyword
keyword
170441
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"